The safety of infliximab infusions in the community setting (Q33916750)

30 July 2017

title

The safety of infliximab infusions in the community setting (English)

1 reference

30 July 2017

James Ducharme

1

1 reference

30 July 2017

Cindy Pelletier

series ordinal

2

1 reference

30 July 2017

Ramesh Zacharias

series ordinal

3

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

Canadian Journal of Gastroenterology

30 July 2017

published in

0 references

volume

24

1 reference

30 July 2017

issue

5

1 reference

30 July 2017

page(s)

307-311

1 reference

Creative Commons Attribution-NonCommercial 4.0 International

30 July 2017

copyright license

start time

1 January 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Treatments for psoriasis and the risk of malignancy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886572

Treatment of severe psoriasis with infliximab

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886572

Biological therapies for inflammatory bowel diseases

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886572

The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886572

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886572

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886572

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886572

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886572

Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886572

Role of cytokines in rheumatoid arthritis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886572

Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886572

Adverse drug events in infliximab-treated patients compared with the general and psoriasis populations.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886572

Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2886572

Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?

29 October 2018

1 reference

12 December 2020

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

1 reference

12 December 2020

Monoclonal antibodies, immunogenicity, and associated infusion reactions

1 reference

12 December 2020

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

12 December 2020

Identifiers

DOI

10.1155/2010/138456

1 reference

30 July 2017

1 reference

30 July 2017

1 reference